Cannabis sativa (marijuana) is a fibrous flowering plant that produces an abundant variety of molecules, some with psychoactive effects. At least 4% of the world's adult population uses cannabis annually, making it one of the most frequently used illicit drugs in the world. The psychoactive effects of cannabis are mediated primarily through cannabinoid receptor (CBR) subtypes. The prevailing view is that CB 1 Rs are mainly expressed in the central neurons, whereas CB 2 Rs are predominantly expressed in peripheral immune cells. However, this traditional view has been challenged by emerging strong evidence that shows CB 2 Rs are moderately expressed and function in specific brain areas. New evidence has demonstrated that brain CB 2 Rs modulate animal drug-seeking behaviors, suggesting that these receptors may exist in brain regions that regulate drug addiction. Recently, we further confirmed that functional CB 2 Rs are expressed in mouse ventral tegmental area (VTA) dopamine (DA) neurons and that the activation of VTA CB 2 Rs reduces neuronal excitability and cocaine-seeking behavior. In addition, CB 2 R-mediated modulation of hippocampal CA3 neuronal excitability and network synchronization has been reported. Here, we briefly summarize recent lines of evidence showing how CB 2 Rs modulate function and pathophysiology in the CNS.
Introduction
The cannabinoid type 2 receptor (CB 2 R) is a G-protein-coupled receptor that was cloned in 1993 [1] . Since then, the expression and function of CB 2 Rs in the brain have been debated. Early studies suggested that CB 2 Rs were absent in the brain because CB 2 mRNA transcripts were not detected in brain tissue using various methods [2] [3] [4] [5] . Based on these findings, CB 2 Rs have been considered the "peripheral" cannabinoid receptor [1, 6, 7] . Recently, this concept has been challenged by the identification of CB 2 Rs throughout the central nervous system (CNS) [5, 6] . Compared with CB 1 Rs, brain CB 2 Rs exhibit several unique features: (1) Brain CB 2 Rs have lower expression levels than CB 1 Rs, suggesting that CB 2 Rs may not mediate the effect of cannabis under normal physiological conditions. (2) Brain CB 2 Rs are highly inducible; thus, under some pathological conditions (eg, addiction, inflammation, anxiety), CB 2 R expression is quickly enhanced in the brain [8] . This finding suggests a close relationship between the alteration of CB 2 R expression/ function and various psychiatric and neurological diseases. (3) Brain CB 2 Rs have a specific distribution. Given that they are chiefly expressed in neuronal somatodendritic areas [9] (postsynaptic), the activation of CB 2 Rs may lead to opposing effects from CB 1 Rs. For example, CB 1 Rs are predominantly expressed on neuronal terminals, especially on GABAergic terminals (presynaptic) in ventral tegmental area (VTA) dopamine (DA) neurons [10] . The activation of CB 1 Rs reduces GABA release onto DA neurons, leading to an increase in DA neuronal firing through a disinhibition mechanism. However, CB 2 Rs are mainly located on postsynaptic somatodendritic areas, and the activation of CB 2 Rs reduces VTA DA neuron firing and excitability [11] . Considering these characteristics, CB 2 Rs appear to be an important substrate for neuroprotection [12] , and targeting CB 2 Rs will likely offer a novel therapeutic strategy for treating neuropsychiatric and neurological diseases without typical CB 1 R-mediated side effects [13] . Thus, an urgent need to understand the functional effects of CB 2 Rs in the brain has emerged.
Review
Brain cannabinoid receptor 2: expression, function and modulation Unfortunately, CB 2 R-mediated modulation of neuronal functions, including ion channels, receptors, synaptic transmission and plasticity, and neuronal networks in the CNS, has not been well investigated, and to date, studies of the functional effects of CB 2 Rs in neurons have ignited debate and controversy due to the following reasons: (1) a lack of highly selective CB 2 R antibodies [14] ; (2) a lack of full knockout (KO) CB 2 R mice as the two types of CB 2 R KO mice that have been recently made available are partial knockouts [7] ; and (3) under some conditions, CB 1 R and CB 2 R can form a heteromer [15] , which makes the identification of CB 2 R function even more complex and difficult. Nevertheless, by combining multiple experimental approaches, several recent papers have described CB 2 R expression and function in the brain neurons. Recently, we reported that functional CB 2 R was expressed in VTA DA neurons, and activation of VTA CB 2 Rs reduces neuronal excitability and cocaine-seeking behavior [11] . It has been reported that CB 2 R modulates hippocampal CA1 synaptic plasticity [16] and CA3 neural plasticity and synchronization [17] . In addition, a recent report showed that CB 2 R-dependent inhibition of DA release underlies the positive allosteric modulation of the M4 muscarinic receptor in antipsychotic-like effects [18] . These accumulating lines of evidence suggest that brain CB 2 Rs are important in the modulation of brain function and disorders.
Brain CB 2 R expression
Although early studies were not able to detect CB 2 mRNA transcripts in brain tissue using various methods [2] [3] [4] [5] , recent lines of evidence show that significant CB 2 mRNA has been detected by in situ hybridization (ISH) in the globus pallidus of non-human primates [19] . RT-PCR analysis has also been used to detect CB 2 mRNA expression in various brain regions, including the retina [20] , cortex [19, [21] [22] [23] , striatum [2, 23] , hippocampus [17, 19, 24] , amygdala [22, 23] , brainstem [25] , and cerebellum [26] . Furthermore, two CB 2 mRNA transcripts (CB 2A and CB 2B ) are transcribed from two independent promoters in rodent and human tissue [21] . Recently, we have confirmed that CB 2 mRNA is relatively highly expressed in VTA DA neurons [11] . Moreover, immunoblot and immunohistochemical (IHC) assays have detected significant CB 2 -like bands or immunostaining in various brain regions [25, [27] [28] [29] [30] , including the VTA [11] . These findings suggest that CB 2 R expression exists not only in peripheral tissue but also in the brain, although the CB 2 R expression level in the brain is much lower than that of CB 1 R. This low-level brain CB 2 R expression suggests that CB 2 R may not participate in important brain physiology function; thus, unlike CB 1 Rs that mediate serious psychiatric side effects after activation, pharmacological intervention of CB 2 Rs has much fewer side effects. In addition to brain neurons, brain glia cells express CB 2 Rs [31, 32] , where CB 2 Rs play an important role in the modulation of central immune function [33] and neuroinflammationassociated diseases [34] [35] [36] .
Brain CB 2 R distribution and function
Although both CB 1 Rs and CB 2 Rs are G-protein (G i/o )-coupled receptors, they exhibit different distributions. In general, the CB 1 Rs are mainly expressed in GABAergic neuronal axon terminals, including in VTA GABA neurons [37, 38] and hippocampal CCK-positive GABA neurons [39] . The activation of CB 1 Rs reduces presynaptic GABA release, eliminates GABAergic inhibitory control of postsynaptic neurons, and excites these postsynaptic neurons through this dis-inhibition role. However, the CB 2 Rs are mainly expressed in the postsynaptic cell body [11, 17] ; thus, the activation of these postsynaptic CB 2 Rs usually hyperpolarizes the membrane potential and inhibits postsynaptic neuronal function. Therefore, this difference in distribution results in opposite effects after CB 1 R and CB 2 R activation. Activation of CB 2 Rs reduces neuronal excitability through different mechanisms. In VTA DA neurons, activation of CB 2 Rs decreases neuronal excitability through the CB 2 R-associated modulation of K + channel function [11] . In prefrontal cortical neurons, intracellular CB 2 Rs are coupled to the G q11 -PLC-IP 3 pathway, which opens the Ca 2+ -dependent Cl -channels, hyperpolarizes the cell membrane and results in neuronal inhibition [40] . In hippocampal CA3/CA2 pyramidal neurons, activation of CB 2 Rs triggers activation of the Na + / Bicarbonate co-transporter and causes a long-term neuronal hyperpolarization. This CB 2 R activation occurs in a purely self-regulatory manner, robustly alters the input/output function of CA3 pyramidal cells, and modulates gamma oscillations in vivo [17] . The relatively high expression of CB 2 Rs in midbrain DA neurons suggests that they modulate a variety of important DA-associated behaviors [41] . It has been reported that CB 2 Rs modulate food intake, body weight [42] [43] [44] [45] , depression [46] , anxiety [22, 47] , and schizophrenia-like behavior [23, 48] . Recent reports emerging from several labs, including ours, have shown that brain CB 2 Rs play a pivotal role in reducing cocaine, alcohol, and nicotine addiction [49] [50] [51] . Collectively, these lines of evidence strongly suggest an important impact of CB 2 Rs in the mesocorticolimbic system, as well as critical roles of CB 2 Rs in various brain functions, including psychiatric, cognitive, and neurobiological activity.
Inducible feature of brain CB 2 Rs and their modulation in neurological and psychiatric disorders
The most attractive property of the CB 2 R is its inducible feature. Brain CB 2 Rs are expressed at low levels under physiological conditions; however, in pathological conditions, such as neuropathic pain [52] , stroke [53] , traumatic brain injury [54] , neurodegenerative diseases [55] [56] [57] or drug addiction [58, 59] , CB 2 R expression up-regulates quickly and profoundly. This inducible feature lets CB 2 Rs serve as a disease-associated target, and pharmacotherapeutic manipulation of CB 2 Rs can treat diseases without side effects. For example, the mesocorticolimbic DA system is a key brain circuit implicated in a number of drug addictions. Alterations of the mesocorticolimbic DA circuit are the major cellular mechanisms to promote or prevent drug reward, dependence, and addiction. Emerging evidence has demonstrated that CB 2 Rs modulate animal drug-seeking behaviors, including cocaine, alcohol, and nicotine [49] [50] [51] , suggesting a significant impact of brain CB 2 Rs in animal drug reward, dependence, and addiction. Given the lack of psychoactivity demonstrated by selective CB 2 R agonists, CB 2 R ligands have been developed as new candidates for the treatment of a variety of neurological and psychiatric disorders [13, 60, 61] , including pain [62] [63] [64] [65] , neuroinflammation [66] , stroke [67, 68] , Alzheimer's disease [69] , Parkinson's disease, and Huntington's disease [36, [70] [71] [72] [73] [74] [75] . Three medicines that activate cannabinoid CB 1 /CB 2 receptors are now used in clinics: Cesamet (nabilone), Marinol (dronabinol; ∆ 9 -tetrahydrocannabinol [∆ 9 -THC]), and Sativex (∆ 9 -THC with cannabidiol). Additionally, a selective CB 2 R agonist "Resunab™" has been designated by the FDA for a fast-track development program in a Phase II human clinical trial for scleroderma. However, significant attention is currently being directed at the possibility of developing medicines from compounds that can activate CB 2 Rs at doses that induce little or no CB 1 R activation. Accumulating lines of evidence have demonstrated that many of the adverse effects induced by mixed CB 1 /CB 2 receptor agonists result from CB 1 R rather than from CB 2 R activation and that CB 2 Rselective agonists have a number of important potential therapeutic applications [60] . Therefore, we anticipate the emergence of new drugs that modulate CB 2 Rs once a better understanding of the cannabinoid receptors is gained.
Limitation of brain CB 2 Rs as a therapeutic target
The major challenge of how to selectively target brain CB 2 Rs without affecting peripheral CB 2 Rs remains, as CB 2 R levels are much higher in peripheral tissues (eg, T-cells in the spleen) than in the brain. Thus, systemic exposure of CB 2 R ligands to activate brain CB 2 Rs will always activate peripheral CB 2 Rs. We have two thoughts regarding this challenge: 1) Brain CB 2 Rs are dramatically inducible, meaning they are up-regulated during disease conditions such as addiction, degeneration and inflammation. This pathology-associated increase significantly enhances the benefit to side-effect ratio [76] . 2) Activation of brain CB 2 Rs protects neurons from pathological conditions (eg, addiction, anxiety, stroke, epilepsy, pain) while also activating peripheral CB 2 Rs (eg, T-cells), which may cause side effects in addition to central therapeutic effects. However, peripheral CB 2 R activation will reduce the immune response and prevent an over-inflammatory reaction, which are beneficial for central protective effects. Therefore, the activation of peripheral CB 2 Rs may not always induce side effects when brain CB 2 Rs are activated, but rather, both central and peripheral CB 2 Rs may work together to protect brain neurons from pathological alterations through both neuronal and immune mechanisms. Figure 1 shows a diagram of the impact of brain CB 2 R distribution, function and disease. 
